Mohamad Alkhouli1, Charanjit S Rihal2, Chad J Zack3, Mackram F Eleid3, Elad Maor3, Mohammad Sarraf3, Allison K Cabalka4, Guy S Reeder3, Donald J Hagler5, Joseph F Maalouf3, Vuyisile T Nkomo3, Hartzell V Schaff6, Sameh M Said6. 1. Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota; Division of Cardiovascular Diseases, West Virginia University, Morgantown, West Virginia. 2. Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota. Electronic address: rihal@mayo.edu. 3. Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota. 4. Division of Pediatric Cardiology, Mayo Clinic College of Medicine, Rochester, Minnesota. 5. Department of Cardiovascular Diseases, Mayo Clinic College of Medicine, Rochester, Minnesota; Division of Pediatric Cardiology, Mayo Clinic College of Medicine, Rochester, Minnesota. 6. Department of Cardiovascular Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota.
Abstract
OBJECTIVES: The aim of this study was to report the use trends and immediate and long-term outcomes of a large cohort of patients who underwent redo surgery or transcatheter repair of paravalvular leaks (PVLs) at a tertiary referral center. BACKGROUND: Percutaneous treatment of mitral PVL has emerged as an alternative to surgical treatment in high-risk surgical candidates. There are limited data on the utilization trends, safety, and efficacy of both procedures in the management of mitral PVL. METHODS: Patients who underwent treatment of mitral PVL at the Mayo Clinic between January 1995 and December 2015 were enrolled. Utilization trends, procedural details, technical success, and in-hospital and long-term outcomes were assessed. RESULTS: Three hundred eighty-one patients underwent percutaneous (n = 195) or surgical (n = 186) treatment of mitral PVLs. The mean age was 66 ± 12 years, and 37% of patients had bioprosthetic valves. Technical success was higher in the surgical group (95.5% vs. 70.1%; p < 0.001). In-hospital major adverse events were more common after surgery (22.5% vs. 7.7%; p < 0.001). In-hospital death occurred in 3.1% and 8.6% of patients undergoing percutaneous and surgical treatment, respectively (p = 0.027). However, in a multivariate logistic regression analysis, only active endocarditis, chronic renal failure, and severe mitral annular calcifications were significant predictors of in-hospital mortality. Reintervention rates were similar (11.3% vs. 17.2% in the percutaneous and surgical groups, respectively; p = 0.10), with the majority of reinterventions in the percutaneous group occurring early because of residual leak or persistent hemolysis. After risk adjustment, there was no significant difference in long-term survival between patients who underwent surgical versus transcatheter treatment of PVLs. CONCLUSIONS: In contemporary practice, patients with symptomatic mitral PVLs are best treated with an integrated team approach incorporating both surgical and percutaneous techniques. Patient selection and timing of intervention are critical to achieve optimal results.
OBJECTIVES: The aim of this study was to report the use trends and immediate and long-term outcomes of a large cohort of patients who underwent redo surgery or transcatheter repair of paravalvular leaks (PVLs) at a tertiary referral center. BACKGROUND: Percutaneous treatment of mitral PVL has emerged as an alternative to surgical treatment in high-risk surgical candidates. There are limited data on the utilization trends, safety, and efficacy of both procedures in the management of mitral PVL. METHODS:Patients who underwent treatment of mitral PVL at the Mayo Clinic between January 1995 and December 2015 were enrolled. Utilization trends, procedural details, technical success, and in-hospital and long-term outcomes were assessed. RESULTS: Three hundred eighty-one patients underwent percutaneous (n = 195) or surgical (n = 186) treatment of mitral PVLs. The mean age was 66 ± 12 years, and 37% of patients had bioprosthetic valves. Technical success was higher in the surgical group (95.5% vs. 70.1%; p < 0.001). In-hospital major adverse events were more common after surgery (22.5% vs. 7.7%; p < 0.001). In-hospital death occurred in 3.1% and 8.6% of patients undergoing percutaneous and surgical treatment, respectively (p = 0.027). However, in a multivariate logistic regression analysis, only active endocarditis, chronic renal failure, and severe mitral annular calcifications were significant predictors of in-hospital mortality. Reintervention rates were similar (11.3% vs. 17.2% in the percutaneous and surgical groups, respectively; p = 0.10), with the majority of reinterventions in the percutaneous group occurring early because of residual leak or persistent hemolysis. After risk adjustment, there was no significant difference in long-term survival between patients who underwent surgical versus transcatheter treatment of PVLs. CONCLUSIONS: In contemporary practice, patients with symptomatic mitral PVLs are best treated with an integrated team approach incorporating both surgical and percutaneous techniques. Patient selection and timing of intervention are critical to achieve optimal results.
Authors: Ignacio Cruz-González; Pablo Luengo-Mondéjar; Blanca Trejo-Velasco; Jean C Núñez-García; Rocío González-Ferreiro; José C Moreno-Samos; Mónica Fuertes-Barahona; Juan C Rama-Merchán; Pablo Antúnez-Muiños; Sergio López-Tejero; Gilles Barreira de Sousa; Javier Rodríguez-Collado; Javier Martín-Moreiras; Alejandro Diego-Nieto; Jesús Herrero-Garibi; Manuel Barreiro-Pérez; Elena Díaz-Peláez; Pedro L Sánchez Fernández Journal: J Clin Med Date: 2022-08-18 Impact factor: 4.964
Authors: Manuela Muratori; Laura Fusini; Maria Elisabetta Mancini; Gloria Tamborini; Sarah Ghulam Ali; Paola Gripari; Marco Doldi; Antonio Frappampina; Giovanni Teruzzi; Gianluca Pontone; Piero Montorsi; Mauro Pepi Journal: J Cardiovasc Dev Dis Date: 2022-01-04